2017
DOI: 10.1038/leu.2017.190
|View full text |Cite
|
Sign up to set email alerts
|

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
24
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(27 citation statements)
references
References 39 publications
3
24
0
Order By: Relevance
“…Additional RAS-signaling pathway activation in form of an internal tandem duplication of Fms Related Receptor Tyrosine Kinase 3 (FLT3-ITD), frequently detected in AML and associated with a worse prognosis, resulted in aggressive lympho-myeloid leukemia [62]. EZH2 mutations also frequently co-occur with TET2 mutations [47,48,60]. Murine analyses conducted by Muto et al revealed that EZH2 or TET2 deficiency alone is sufficient to induce an MDS/MPN phenotype with lethality during long observation periods, while depletion of both EZH2 and TET2 synergistically advances myelodysplasia and accelerates the progression of both MDS and MDS/MPN.…”
Section: Mutual Exclusion and Concomitance Of Ezh2 And Other Leukemiamentioning
confidence: 99%
“…Additional RAS-signaling pathway activation in form of an internal tandem duplication of Fms Related Receptor Tyrosine Kinase 3 (FLT3-ITD), frequently detected in AML and associated with a worse prognosis, resulted in aggressive lympho-myeloid leukemia [62]. EZH2 mutations also frequently co-occur with TET2 mutations [47,48,60]. Murine analyses conducted by Muto et al revealed that EZH2 or TET2 deficiency alone is sufficient to induce an MDS/MPN phenotype with lethality during long observation periods, while depletion of both EZH2 and TET2 synergistically advances myelodysplasia and accelerates the progression of both MDS and MDS/MPN.…”
Section: Mutual Exclusion and Concomitance Of Ezh2 And Other Leukemiamentioning
confidence: 99%
“…Inactivating mutations of EZH2 are also observed in MDS, which are associated with its decreased expression level. [39][40][41][42][43] Another novel target of mis-splicing is LUC7L2, a spliceosome gene which is located on chromosome 7q34 and is also mutated infrequently in MDS. 34,44 Usage of cryptic splice site in SRSF2 del and P95 mutant samples produces transcripts with premature stop codon, potentially leading to decreased expression of LUC7L2.…”
Section: Gene Expression Profiling Reveals Dysregulated Heme Metabomentioning
confidence: 99%
“…Earlier, we and others have shown that Rac GTPases critically regulate leukemia cell engraftment and survival (15)(16)(17)(18). VAV3, Rho/Rac GTPase GEF, was implicated in leukemogenesis (41,42). DOCK2 is a noncanonical GEF for Rac GTPases, and DOCK2 inhibition in vivo attenuates AML cell survival (43,44).…”
Section: Discussionmentioning
confidence: 98%